MorphoSys AG Logo

MorphoSys AG

MOR

(0.8)
Stock Price

18,96 USD

-66.19% ROA

742.62% ROE

-5.65x PER

Market Cap.

2.603.928.071,19 USD

-96.49% DER

0% Yield

-226.08% NPM

MorphoSys AG Stock Analysis

MorphoSys AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MorphoSys AG Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (92.99%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ROA (9.61%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

3 PBV

The stock's elevated P/BV ratio (23.09x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

4 DER

The company has a high debt to equity ratio (888%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-17) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

MorphoSys AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MorphoSys AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Sell

MorphoSys AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MorphoSys AG Revenue
Year Revenue Growth
2002 16.757.097
2003 15.308.464 -9.46%
2004 21.978.796 30.35%
2005 7.978.641 -175.47%
2006 53.031.172 84.95%
2007 61.962.008 14.41%
2008 71.645.341 13.52%
2009 81.024.081 11.58%
2010 87.036.308 6.91%
2011 100.777.157 13.63%
2012 51.916.986 -94.11%
2013 77.960.057 33.41%
2014 63.977.978 -21.85%
2015 106.222.897 39.77%
2016 49.743.515 -113.54%
2017 66.790.840 25.52%
2018 76.442.505 12.63%
2019 71.755.303 -6.53%
2020 327.698.465 78.1%
2021 179.600.000 -82.46%
2022 278.267.003 35.46%
2023 255.200.000 -9.04%
2023 238.278.313 -7.1%
2024 110.158.964 -116.3%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MorphoSys AG Research and Development Expenses
Year Research and Development Expenses Growth
2002 19.591.834
2003 8.998.012 -117.74%
2004 12.391.295 27.38%
2005 -14.029.310 188.32%
2006 -17.458.350 19.64%
2007 -22.237.170 21.49%
2008 27.599.615 180.57%
2009 38.967.305 29.17%
2010 46.899.723 16.91%
2011 57.477.141 18.4%
2012 37.673.345 -52.57%
2013 49.151.721 23.35%
2014 55.962.693 12.17%
2015 78.655.788 28.85%
2016 95.723.069 17.83%
2017 116.808.575 18.05%
2018 106.397.017 -9.79%
2019 108.431.600 1.88%
2020 141.426.832 23.33%
2021 225.200.000 37.2%
2022 297.812.160 24.38%
2023 252.800.000 -17.81%
2023 283.614.139 10.86%
2024 340.605.880 16.73%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MorphoSys AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 18.742.819
2003 7.601.078 -146.58%
2004 7.522.188 -1.05%
2005 -10.072.583 174.68%
2006 -21.418.416 52.97%
2007 0 0%
2008 20.484.400 100%
2009 23.910.845 14.33%
2010 23.226.029 -2.95%
2011 24.584.145 5.52%
2012 12.081.649 -103.48%
2013 11.311.000 -6.81%
2014 9.689.000 -16.74%
2015 10.431.000 7.11%
2016 9.618.000 -8.45%
2017 12.348.000 22.11%
2018 21.927.731 43.69%
2019 36.664.666 40.19%
2020 51.403.257 28.67%
2021 78.300.000 34.35%
2022 83.896.000 6.67%
2023 60.000.000 -39.83%
2023 86.218.000 30.41%
2024 742.135.612 88.38%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MorphoSys AG EBITDA
Year EBITDA Growth
2002 -23.391.477
2003 -976.450 -2295.56%
2004 3.278.454 129.78%
2005 38.929.703 91.58%
2006 87.379.479 55.45%
2007 97.341.126 10.23%
2008 23.230.385 -319.03%
2009 18.392.228 -26.31%
2010 19.325.762 4.83%
2011 18.086.329 -6.85%
2012 8.903.527 -103.14%
2013 15.517.783 42.62%
2014 -796.236 2048.89%
2015 22.929.951 103.47%
2016 -54.979.741 141.71%
2017 -63.024.787 12.76%
2018 -54.937.948 -14.72%
2019 -98.874.946 44.44%
2020 127.737.978 177.4%
2021 -179.200.000 171.28%
2022 172.797.346 203.71%
2023 -201.600.000 185.71%
2023 -97.738.116 -106.27%
2024 -1.053.513.840 90.72%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MorphoSys AG Gross Profit
Year Gross Profit Growth
2002 16.757.097
2003 15.308.464 -9.46%
2004 21.978.796 30.35%
2005 10.492.813 -109.47%
2006 61.009.813 82.8%
2007 69.909.136 12.73%
2008 64.506.857 -8.37%
2009 74.280.245 13.16%
2010 79.752.097 6.86%
2011 93.752.816 14.93%
2012 51.916.986 -80.58%
2013 77.931.057 33.38%
2014 63.900.978 -21.96%
2015 106.145.897 39.8%
2016 49.646.515 -113.8%
2017 66.757.840 25.63%
2018 74.645.876 10.57%
2019 59.670.105 -25.1%
2020 318.524.319 81.27%
2021 147.400.000 -116.1%
2022 229.647.003 35.81%
2023 194.800.000 -17.89%
2023 179.923.313 -8.27%
2024 94.690.088 -90.01%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MorphoSys AG Net Profit
Year Net Profit Growth
2002 -24.377.294
2003 -4.148.032 -487.68%
2004 282.112 1570.35%
2005 4.676.369 93.97%
2006 6.027.934 22.42%
2007 11.474.610 47.47%
2008 13.153.353 12.76%
2009 8.964.095 -46.73%
2010 9.196.300 2.52%
2011 8.216.397 -11.93%
2012 1.942.145 -323.06%
2013 13.321.930 85.42%
2014 -3.012.629 542.2%
2015 14.900.768 120.22%
2016 -60.382.776 124.68%
2017 -69.826.469 13.52%
2018 -56.172.121 -24.31%
2019 -103.014.058 45.47%
2020 97.890.576 205.23%
2021 -514.500.000 119.03%
2022 -151.057.591 -240.6%
2023 -478.400.000 68.42%
2023 -189.734.199 -152.14%
2024 -1.259.851.184 84.94%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MorphoSys AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -1
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 -1 0%
2017 -1 0%
2018 0 0%
2019 -1 0%
2020 1 0%
2021 -4 100%
2022 -1 -200%
2023 -4 66.67%
2023 -1 -200%
2024 -8 87.5%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MorphoSys AG Free Cashflow
Year Free Cashflow Growth
2002 -16.167.566
2003 5.131.366 415.07%
2004 2.949.709 -73.96%
2005 4.216.530 30.04%
2006 15.438.380 72.69%
2007 16.856.070 8.41%
2008 24.765.004 31.94%
2009 -4.796.745 616.29%
2010 -11.277.982 57.47%
2011 23.465.477 148.06%
2012 -521.186 4602.32%
2013 83.574.060 100.62%
2014 -34.697.019 340.87%
2015 -32.279.246 -7.49%
2016 -49.529.198 34.83%
2017 -51.594.702 4%
2018 -35.734.838 -44.38%
2019 -83.804.283 57.36%
2020 -14.066.813 -495.76%
2021 -507.601.249 97.23%
2022 -381.933.923 -32.9%
2023 -298.709.634 -27.86%
2023 -126.067.943 -136.94%
2024 -64.474.834 -95.53%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MorphoSys AG Operating Cashflow
Year Operating Cashflow Growth
2002 -15.245.796
2003 5.813.443 362.25%
2004 4.676.455 -24.31%
2005 4.216.530 -10.91%
2006 15.438.380 72.69%
2007 16.856.070 8.41%
2008 28.647.573 41.16%
2009 -979.031 3026.12%
2010 2.532.078 138.67%
2011 27.070.459 90.65%
2012 1.790.014 -1412.3%
2013 89.137.617 97.99%
2014 -14.218.356 726.92%
2015 -23.513.849 39.53%
2016 -46.615.708 49.56%
2017 -38.445.855 -21.25%
2018 -33.269.514 -15.56%
2019 -80.138.639 58.49%
2020 35.269.717 327.22%
2021 -481.445.084 107.33%
2022 -366.705.261 -31.29%
2023 -295.836.943 -23.96%
2023 -125.965.846 -134.85%
2024 -64.426.643 -95.52%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MorphoSys AG Capital Expenditure
Year Capital Expenditure Growth
2002 921.770
2003 682.077 -35.14%
2004 1.726.746 60.5%
2005 0 0%
2006 0 0%
2007 0 0%
2008 3.882.569 100%
2009 3.817.714 -1.7%
2010 13.810.060 72.36%
2011 3.604.982 -283.08%
2012 2.311.200 -55.98%
2013 5.563.557 58.46%
2014 20.478.663 72.83%
2015 8.765.397 -133.63%
2016 2.913.490 -200.86%
2017 13.148.847 77.84%
2018 2.465.324 -433.35%
2019 3.665.644 32.75%
2020 49.336.530 92.57%
2021 26.156.165 -88.62%
2022 15.228.662 -71.76%
2023 2.872.691 -430.12%
2023 102.097 -2713.69%
2024 48.191 -111.86%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MorphoSys AG Equity
Year Equity Growth
2002 20.615.466
2003 30.182.553 31.7%
2004 39.378.486 23.35%
2005 64.007.780 38.48%
2006 100.051.320 36.03%
2007 145.537.450 31.25%
2008 161.987.188 10.15%
2009 173.934.365 6.87%
2010 185.922.094 6.45%
2011 197.135.594 5.69%
2012 202.010.017 2.41%
2013 352.145.420 42.63%
2014 348.803.135 -0.96%
2015 362.736.007 3.84%
2016 415.460.165 12.69%
2017 358.671.039 -15.83%
2018 488.372.634 26.56%
2019 394.701.772 -23.73%
2020 621.322.017 36.47%
2021 244.875.943 -153.73%
2022 157.409.549 -55.57%
2023 31.669.185 -397.04%
2023 49.049.239 35.43%
2024 -261.666.889 118.74%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MorphoSys AG Assets
Year Assets Growth
2002 42.393.313
2003 45.758.920 7.36%
2004 55.795.693 17.99%
2005 80.116.568 30.36%
2006 127.843.512 37.33%
2007 184.712.832 30.79%
2008 203.292.892 9.14%
2009 206.090.595 1.36%
2010 212.553.833 3.04%
2011 228.410.450 6.94%
2012 224.288.780 -1.84%
2013 447.656.746 49.9%
2014 426.477.973 -4.97%
2015 400.079.490 -6.6%
2016 463.600.117 13.7%
2017 415.398.211 -11.6%
2018 538.763.757 22.9%
2019 496.439.302 -8.53%
2020 1.659.513.020 70.09%
2021 2.556.254.216 35.08%
2022 2.396.932.263 -6.65%
2023 2.142.502.407 -11.88%
2023 2.026.311.213 -5.73%
2024 1.831.530.557 -10.63%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MorphoSys AG Liabilities
Year Liabilities Growth
2002 21.777.847
2003 15.576.367 -39.81%
2004 16.417.207 5.12%
2005 16.108.788 -1.91%
2006 27.792.192 42.04%
2007 39.175.382 29.06%
2008 41.305.704 5.16%
2009 32.156.230 -28.45%
2010 26.631.739 -20.74%
2011 31.274.856 14.85%
2012 22.278.763 -40.38%
2013 95.511.326 76.67%
2014 77.674.838 -22.96%
2015 37.343.483 -108%
2016 48.139.952 22.43%
2017 56.727.172 15.14%
2018 50.391.123 -12.57%
2019 101.737.530 50.47%
2020 1.038.191.003 90.2%
2021 2.311.378.273 55.08%
2022 2.239.522.714 -3.21%
2023 2.110.833.222 -6.1%
2023 1.977.261.974 -6.76%
2024 2.093.197.446 5.54%

MorphoSys AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.35
Net Income per Share
-3.06
Price to Earning Ratio
-5.65x
Price To Sales Ratio
12.79x
POCF Ratio
-9.27
PFCF Ratio
-9.2
Price to Book Ratio
-9.94
EV to Sales
13.43
EV Over EBITDA
-8.34
EV to Operating CashFlow
-9.75
EV to FreeCashFlow
-9.66
Earnings Yield
-0.18
FreeCashFlow Yield
-0.11
Market Cap
2,60 Bil.
Enterprise Value
2,73 Bil.
Graham Number
10.94
Graham NetNet
-9.57

Income Statement Metrics

Net Income per Share
-3.06
Income Quality
0.61
ROE
7.43
Return On Assets
-0.25
Return On Capital Employed
-0.33
Net Income per EBT
1.01
EBT Per Ebit
1.02
Ebit per Revenue
-2.2
Effective Tax Rate
-0.06

Margins

Sales, General, & Administrative to Revenue
1.28
Research & Developement to Revenue
1.4
Stock Based Compensation to Revenue
0.69
Gross Profit Margin
0.8
Operating Profit Margin
-2.2
Pretax Profit Margin
-2.24
Net Profit Margin
-2.26

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.86
Free CashFlow per Share
-1.88
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.01
Capex to Depreciation
0.28
Return on Invested Capital
51.61
Return on Tangible Assets
-0.66
Days Sales Outstanding
55.28
Days Payables Outstanding
642.69
Days of Inventory on Hand
0
Receivables Turnover
6.6
Payables Turnover
0.57
Inventory Turnover
41223618
Capex per Share
0.02

Balance Sheet

Cash per Share
4,19
Book Value per Share
-1,74
Tangible Book Value per Share
-9.29
Shareholders Equity per Share
-1.74
Interest Debt per Share
2.39
Debt to Equity
-0.96
Debt to Assets
0.14
Net Debt to EBITDA
-0.4
Current Ratio
1.38
Tangible Asset Value
-1,40 Bil.
Net Current Asset Value
-1,42 Bil.
Invested Capital
1334252730
Working Capital
0,19 Bil.
Intangibles to Total Assets
0.62
Average Receivables
0,04 Bil.
Average Payables
0,05 Bil.
Average Inventory
31034058
Debt to Market Cap
0.1

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MorphoSys AG Dividends
Year Dividends Growth

MorphoSys AG Profile

About MorphoSys AG

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

CEO
Mr. Arkadius Pichota M.B.A.,
Employee
464
Address
Semmelweisstrasse 7
Planegg, 82152

MorphoSys AG Executives & BODs

MorphoSys AG Executives & BODs
# Name Age
1 Mr. Klaus De Wall
Head of Accounting & Tax
70
2 Dr. Günter Wellnhofer
Head of Technical Operations
70
3 Dr. Barbara Krebs-Pohl Ph.D.
Chief Business Officer
70
4 Dr. Harald Watzka
Head of Alliance Management
70
5 Mr. Arkadius Pichota M.B.A., Ph.D.
Chief Executive Officer
70
6 Dr. Margit Urban
Head of Discovery Alliances & Technologies
70
7 Mr. Lukas Gilgen
Chief Financial Officer
70
8 Dr. Julia Neugebauer Ph.D.
Head of Investor Relations
70
9 Ms. Charlotte Lohmann
Chief Legal and Human Resources Officer & Member of Management Board
70
10 Dr. Tim Demuth M.D., Ph.D.
Chief Research & Development Officer
70

MorphoSys AG Competitors